エレクトロアキュプチャーの予備治療は,横部下垂体におけるマイクログリアの吸収を阻害することによって,心筋不全-再注射損傷を緩和する
Xiang Zhou1,2, Peiyi Yang3, Chaonan Dong3
1College of Traditional Chinese Medicine, Anhui University of Chinese Medicine, Hefei, China.
CNS neuroscience & therapeutics
|September 4, 2025
まとめ
電気治療 (EA- pre) は,横下垂体内のマイクログリアを調節することによって,心筋不全再注射損傷 (MIRI) に対して保護します. この治療は神経炎症と交感神経系の過剰活性化を軽減し,MIRIの潜在的な治療戦略を提供します.
科学分野:
- 神経科学
- 心臓病科
- 免疫学
背景:
- 神経炎症,特にマイクログリアの活性化が伴う.
- MIRIを予防するための現在の臨床戦略は不明である.
- マイクログリアとグルタミン酸 (Glu) ニューロンは,側視床下部 (LH) のMIRIの病原化に関与しています.
研究 の 目的:
- MIRIの治療戦略として電気治療 (EA-pre) を調査する.
- LHマイクログリアとGluニューロンに焦点を当てて,MIRIを緩和するEA-preの基礎的なメカニズムを解明する.
- MIRI予防のための潜在的な治療目標を特定する.
主な方法:
- 冠動脈結合と再注血によるMIRIマウスモデルの確立.
- LHにおけるマイクログリア活性化を評価するための免疫光染色.
- 化学遺伝学と繊維光測定の記録で ニューロンの活動とマイクログリアの機能を調べる
- シナプス変化と交感神経系 (SNS) の出力分析
主要な成果:
- MIRIマウスの心臓機能が著しく改善されました.
- EA- preはマイクログリアの活性化を抑制し,LH Gluニューロン周辺の抑制シナプスの吸収を減少させた.
- LHマイクログリアの標的型活性化により,EA- preの保護効果が逆転し,SNSの活性化によりMIRIが悪化した.
結論:
- MIRIに対するEA- preは,LHにおけるマイクログリアの活性を抑制することによって,心臓保護効果を発揮する.
- このメカニズムは,LH Gluニューロンの抑制シナプスを保存し,それによってSNSの過剰活性化を減少させます.
- LHマイクログリアを調節することは,MIRIに対する有望な治療法です.
さらに関連する動画
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
285
07:12Studying the Coding Profiles of Somatic Stimulation on Cardiac-locked Neuronal Responses in the Rat Spinal Dorsal Horn
Published on: May 23, 2025
223
関連する概念動画
01:14Prevention of Further Absorption of Poison
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.